Table 1 Characteristics of 72 patients with Allo-HSCT
Patients | |
Age (median years, range) | 44 (13–63) |
Sex (male) | 35 (48.6%) |
Haematologic disease | |
Acute Myeloblastic Leukaemia | 18 (25.0%) |
Acute Lymphoblastic Leukaemia | 13 (18.1%) |
Myelodysplastic syndrome | 8 (11.1%) |
Myeloproliferative syndrome | 8 (11.1%) |
Hodgkin Lymphoma | 6 (8.3%) |
Multiple Myeloma | 5 (6.9%) |
Chronic Lymphoproliferative Disorder | 7 (9.7%) |
NHLa | 3 (4.2%) |
Bone Marrow Aplasia | 3 (4.2%) |
Waldeström Disease | 1 (1.4%) |
Type of Transplant | |
Myeloablative | 38 (52.8%) |
Non-myeloablative | 34 (47.2%) |
Conditioning | |
Busulfan + Cyclophosphamide + /−ATG | 23 (32.0%) |
Fludarabine + Melphalan + /−ATG | 18 (25.0%) |
Radiotherapy + Cyclophosphamide + /−ATG | 12 (16.7%) |
Busulfan + fludarabine | 11 (15.3%) |
Others | 8 (11.1%) |
MBL levels (ng/mL) (median, IQRb) | |
Pre-transplant | 1135 (2918–466) |
Early period | 1997.5 (4056–464) |
Intermediate period | 1665 (3765–337.3) |
Late period | 1264 (3219.5–468.4) |